To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

February 23, 2018

Today's Rundown

Featured Story

Bristol-Myers chops clinical staff as site closure enters endgame

Bristol-Myers Squibb is set to lay off 107 staffers at its Wallingford, Connecticut, site as its planned closure of the facility gathers pace. Having earmarked the site for staff reductions in 2015, Bristol-Myers is now doling out pink slips at an accelerating rate as it gets closer to shuttering by the end of the year.

Top Stories

Mesoblast prepares first filings for GVHD drug after phase 3 win

A late-stage study of Mesoblast’s off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD) has hit its main goal, setting up an imminent U.S. filing.

GeneTx Biotherapeutics launches to take on Angelman syndrome

GeneTx will develop an antisense drug for Angelman syndrome, a genetic disorder that affects the nervous system.

[Sponsored] Optimizing Humanized Model Selection for Enhanced Preclinical Immunotherapy Assessment

Tumor-bearing humanized models are vital preclinical platforms for assessing human-specific immunotherapies. Review immediately transferable humanized model strategies for accelerating immunotherapy drug discovery programs.

Merck's ERK inhibitor shows promise in combination against resistant cancers

One-fifth of patients in a phase 1 study responded to Merck's ERK inhibitor, a comparable response rate to other cancer drugs, such as MEK inhibitors. The results suggest the drug could be used in tandem with another to fight cancers with a specific mutation.

Teva shutters New York, D.C. offices and dismisses lobbyists as part of U.S. consolidation drive

Teva is working to consolidate seven U.S. offices under one roof, and that means saying bye-bye to its New York and Washington, D.C., locations.

EuroBiotech Report—GW’s trial fail, Arix-Ipsen, Medigene T-cell trial and Santhera in DMD

In this week's EuroBiotech Report, GW’s proof-of-concept trial faIls, Arix hooks up with Ipsen, Medigene trial gets green light and more. 

FiercePharmaAsia—More Takeda deals, China’s pharma supply issues, Merck KGaA expansion

Takeda made R&D deals in neurological disorders and with academic institutions, China's crackdown on pollution has caused some supply issues for the pharma industry, Merck KGaA plans further manufacturing expansions in Asia and more.

Chutes & Ladders—Pfizer’s early clinical head lands as Magenta CMO

Fierce 15 winner Magenta Therapeutics recruits Pfizer executive John Davis, M.D., as its CMO; former Teva executive Siggi Olafsson re-emerges at Hikma Pharmaceuticals; plus more hirings, firings and retirings throughout the industry.

Resources

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market?

[Whitepaper] How Life Sciences Companies Use Box for Regulated Content in the Cloud

Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process.

[Whitepaper] CFO's, Is This Part Of Your Corporate TO DO List?

Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.